资讯

The Pharma Letter2 小时
High costs and limited access threaten progress in HIV treatment despite new drug advances
Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious ...
Frontiers17 小时
Evolution of antiretroviral therapy: Transitioning from three-drug to two-drug HIV regimens
The field of HIV treatment has witnessed a significant transformation since the mid-1990s with the introduction of combination antiretroviral therapy ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
Mirage News4 天
FDA Approves Biannual HIV Prevention Injection
Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...
Rolling Out11 天
99.9% breakthrough transforms HIV prevention forever
FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant ...
Discover Magazine on MSN11 天
FDA Approves Breakthrough HIV Drug, but It Could Be Hard to Access
Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.
FDA Approves ‘Breakthough’ Drug to Prevent HIV
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.